The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Focal adhesion kinase (FAK) inhibitors are in clinical trials for cancer treatment.
• The impact of FAK inhibitors, specifically PF-562,271, on T cell function remains largely unknown.
• Understanding T cell responses to FAK inhibitors is crucial for predicting therapeutic outcomes.

Purpose of the Study:

• To investigate the effects of the FAK inhibitor PF-562,271 on primary human and mouse T cell activation.
• To elucidate the mechanisms by which PF-562,271 influences T cell receptor signaling and cell-cell interactions.
• To assess the potential immunomodulatory consequences of PF-562,271 treatment.

Main Methods:

• Primary human and mouse T cells were treated with PF-562,271.
• T cell adhesion to ICAM-1 and interactions with antigen-presenting cells (APCs) were measured.
• Signaling pathway phosphorylation, T cell proliferation, and responses to PMA/ionomycin stimulation were analyzed.
• Genetic depletion of FAK was used for comparison.

Main Results:

• PF-562,271 significantly inhibited T cell receptor (TCR) signaling-induced T cell adhesion and conjugation with APCs.
• PF-562,271 blocked phosphorylation of key signaling molecules including ZAP-70, Lck, and ERK.
• While PF-562,271 impaired T cell proliferation, this effect was not solely due to FAK inhibition and was independent of proximal TCR signaling.

Conclusions:

• FAK plays a regulatory role in integrin-mediated T cell adhesion following TCR activation.
• PF-562,271 exhibits immunomodulatory effects beyond FAK inhibition, impacting T cell proliferation through a mechanism not fully explained by FAK.
• These findings highlight potential implications of PF-562,271's immunomodulatory actions for its clinical use in cancer therapy.